Search

Therapeutic Drug Monitoring 2nd Edition is an updated reference on TDM analytical techniques in diverse clinical settings. This new edition reviews the exciting new developments in the area, including seven new chapters covering immunoassay design and applications, combined chromatographic techniques in therapeutic monitoring, drug monitoring in alternative specimens, pharmacogenomics of anticancer drugs, pharmacogenomics testing for patient management, selected antifungal agents, pharmacodynamic monitoring, and therapeutic drug monitoring of selected anticoagulants. All remaining chapters in the first edition were thoroughly revised and updated. Therapeutic Drug Monitoring 2nd Edition is the ideal reference for clinical pathologists, pharmacologists, and toxicologists involved with TDM. Scientists working in diagnostic companies, developing reagents for monitoring therapeutic drugs will also find relevant information in this book. - Includes new chapters covering antifungal, anticoagulant, and anticancer drugs monitoring - Discusses limitations of current immunoassays, new and sophisticated chromatographic techniques, the clinical effectiveness of newer antiretroviral agents, anticonvulsants and antidepressants - Provides full coverage of pharmacogenomics and personalized medicine, principles of pharmacokinetics and pharmacodynamics, and the application of biomarkers in TDM

This state-of-the-art text describes the science behind the system and drug-dependent components of PBPK models, its applications in translational and regulatory science, e.g., guiding drug discovery and development, and supporting precision medicine initiatives. To incorporate state-of-the-art knowledge, each chapter is written by leaders in the field and illustrated by clear case studies. Connecting basic and applied science, this book explores the potential of PBPK modeling for improving therapeutics and is designed for a wide audience encompassing graduate students as well as biopharmaceutics scientists and clinical pharmacologists.Features:1. Provides a basic understanding of the physiologically-based pharmacokinetic modeling and its applications2. Assists the reader in understanding product performance to allow for rapid product development and establish bioequivalence3. Well-constructed content and added value of real examples4. Illustrates how using available resources via modeling and simulation leads to a reduction in the costs related to drug development, which directly affects the costs to patients

The science of drug safety and pharmacovigilance has rapidly evolved in the 21st century. The knowledge and principles it contains are of increasing importance in clinical and practice settings. The aim of this book is to deal with the gap in knowledge about pharmacovigilance and drug safety, including the application of pharmacovigilance knowledge to individual patient cases in clinical practice. A holistic approach is taken with each chapter written from the perspective of a practitioner, industry personnel, researcher, or regulator, creating a synergy between drug safety, pharmacovigilance, and clinical practice. Chapters offer key material on adverse drug reactions, medication errors, prescribing safety, pharmacovigilance as well as data sources used in drug safety and pharmacovigilance. Each chapter is structured as a self-contained learning resource, with learning objectives, and worked cases. The book is suitable for undergraduate healthcare professions, postgraduate students, researchers, clinical practitioners – including those with prescribing responsibilities. It will also be useful for professionals moving from a clinical practice role to a specialist pharmacovigilance role. For those already in a pharmacovigilance role, the book offers insight into the theory and practice of drug safety and pharmacovigilance in clinical settings.

This book is a complete resource on pharmacokinetics, pharmacodynamics and pharmacogenomics in clinical practice. It consists of seven chapters that cover various aspects of pharmacokinetics and its clinical applications. The chapters are structured to provide clear objectives and keywords are bolded throughout the text to facilitate understanding. The topics covered include the significance of pharmacokinetics in clinical practice, factors affecting pharmacokinetic parameters, pharmacokinetic drug interactions, therapeutic drug monitoring, dosage adjustment in different population groups, the influence of hepatic diseases on pharmacokinetics and the impact of pharmacogenomics on pharmacokinetics and pharmacodynamics. The book is written in simple language to make the concepts accessible to all readers. This book is a comprehensive resource for students pursuing a doctoral degree in pharmacy, as well as academicians and researchers in clinical pharmacokinetics.

Featured here is a modern translation of a medieval herbal, with a study showing how this technical treatise on herbs was turned into a literary curiosity in the nineteenth century. The contours of this second edition replicate the first; however, it has been revised and updated throughout to reflect new scholarship and new findings. New information is presented on Oswald Cockayne, the nineteenth-century philologist who first translated the Old English medical texts for the modern world.Here the medieval text is read as an example of technical writing (i.e., intended to convey instructions/information), not as literature. The audience it was originally aimed at would know how to diagnose and treat medical conditions and knew or was learning how to follow its instructions. For that reason, while working on the translation, specialists in relevant fields were asked to shed light on its terse wording, for example, herbalists and physicians. Unlike many current studies, this work discusses the Herbarium and other medical texts in Old English as part of a tradition developed throughout early-medieval Europe associated with monasteries and their libraries.The book is intended for scholars in cross-cultural fields; that is, with roots in one field and branches in several, such as nineteenth-century or medieval studies, for historians of herbalism, medicine, pharmacy, botany, and of the Western Middle Ages, broadly and inclusively defined, and for readers interested in the history of herbalism and medicine.

This book provides a concise overview of recent advances in Pharmacokinetics (PK) and Pharmacodynamics (PD). The pharmacokinetics section covers the state of the art in Physiologically Based Pharmacokinetic (PBPK) modeling (Chapter 1) as well as the assessment of food effect on drug absorption using PBPK modeling (Chapter 2). Chapters 3 and 4 describe the recent development of Physiologically Based Finite Time Pharmacokinetic (PBFTPK) models and their applications to pharmacokinetic data. The pharmacodynamics section focuses on PK/PD modeling. Chapter 5 provides an overview of PK/PD modeling and simulation in clinical practice and studies. Chapter 6 deals with the subject/physiology variability issue encountered in PK/PD studies, while Chapter 7 reviews the influence of clinical pharmacology in the modernization of drug development and regulation. This book is an essential reference for pharmaceutical scientists.

This book provides a practically applicable guide to the applications of pharmogenomics across medicine. Background information is provided on the mechanisms associated with membrane transporters, drug-metabolizing enzymes and their importance in pharmagenomics. Detailed guidance is subsequently presented on how to apply these techniques in disciplines including cardiology, gastroenterology, oncology, transplantation surgery, infectious diseases, anesthesia and analgesia, neurology, psychiatry, primary care, and public health. Clear easy-to-follow instructions are given on how to use big data technologies and public health databases in day-to-day clinical practice. Pharmacogenomics in Clinical Practice concisely covers how pharmacogenomic technologies and techniques can be applied in daily medical practice. It is therefore an ideal up-to-date resource for any medical practitioner, trainee or researcher across all medical disciplines whowant to better understand how to use these techniques.

This book covers several important aspects of pharmaceutical research and innovations. It presents important topics on drug delivery, novel microsponge, nanocrystals, polymeric nanoparticles, peptide synthesis, biopharmaceuticals, pharmacodynamics, yeast flocculation, neuromodulators, innovative drug discovery, pharmacoinformatics, aminoquinoline, thiourea crystals for API synthesis, FDCs and formulations research, ayurveda and natural products, and innovations to militate anti-microbial resistance (AMR). A chapter is devoted to the applications of Artificial Intelligence and Machine Learning in diverse sectors of the pharmaceutical industry, including drug discovery and development, drug repurposing, and improving pharmaceutical productivity. The book also reviews the role of pharmacogenomics and pharmacogenetics in drug development and precision medicine. Further, the book presents an updated summary of recent advances in the fields of nanomedicines and nano-based drug delivery systems. This book is useful to pharmaceutical sciences students, researchers, educators, and professionals in the pharmaceutical industry to understand the intricacies of new drug research and innovations.

This new edition of Pharmacoresistance in Epilepsy addresses all issues relating to drug-resistance in epilepsy, including studies in patients as well in experimental models and presents the basis for an understanding of recent developments in the pathogenesis and treatment of this condition. Important issues associated with drug-resistant epilepsy are reviewed and updated, such as abnormalities in inhibitory mechanisms, neurotoxicity and changes the immune system associated with this disorder, and the development of drug-resistance as consequence of chronic exposure to antiseizure-medications. Considering that a major obstacle is that epilepsy associated with drug-resistance cannot be controlled with the traditional antiseizure medications, specific chapters describe therapeutic strategies to prevent or reduce the progression of the disease with complementary medical therapies, such as transcranial focal stimulation to promote neuroprotection. Pharmacoresistance in Epilepsy is a valuable resource for anyone working in the field, whether studying epilepsy in the lab or treating it in an office.

This edited volumeaims to describe physiological and pathophysiological mechanisms that underlie human maternal-fetal interactions. The book emphasizes the structure and development of the fetoplacental unit, the endocrine and nutritional regulation of fetal development, nitric oxide signalling, solute carriers function and ion channels regulation in healthy pregnancies and diseases, like preeclampsia, gestational diabetes, and maternal obesity, among others. Also, we highlight novel mechanisms associated with language impairment in children, the use of serotonin inhibitors or cannabis during pregnancy, and maternal conditions'potential impact on cerebrovascular development in newborns and infants. The cellular and molecular understanding of maternal-fetal physiology and pathophysiology will allow the readers to understand the impact of diseases or conditions that are highly prevalent in pregnant women.

This significantly revised fourth edition provides a practically orientated guide to interactions associated with antiseizure medications. It describes pharmacokinetic and pharmacodynamic antiseizure medication (ASM) interactions, including details of the magnitude and mechanism of interactions, and also of drug combinations that are not associated with interactions and therefore can be co-prescribed without undue concern. Presented in alphabetical order and by drug class, drug interactions that occur between ASMs and also between ASMs and non- ASMs are described in three sections: Drug interactions between ASMs; Drug interactions between ASMs and non- ASM Drugs: Interactions affecting ASMs; Drug interactions between ASMs and non ASM Drugs: Interactions affected by ASMs. The latest data on all drug interactions is presented. New agents discussed include cannabidiol, cenobamate, everolimus and fenfluramine,. Antiseizure Medication Interactions: A Clinical Guide, 4th Edition concisely presents the most recent developments and data available on the topic. Therefore, enabling physicians and allied health professionals to make more rational choices when ASM polytherapy regimens are required. It will be of interest to medical professionals in disciplines including neurology, psychiatry and pediatrics.

This book gives an overview of therapeutic drug monitoring (TDM) and its clinical application. It also highlights recent advances in toxicological studies, as they relate to therapeutic drug monitoring. This is one of the few books available on the market that covers TDM. Therapeutic drug monitoring (TDM) is a clinical decision-making tool that enables dosage regimen adjustments based on clinical and laboratory measurements. TDM not only involves the measuring of drug concentrations but also interpretation of the results. There is a strong correlation between drug concentrations in body fluids and outcome than between dose and outcome. The chapters include coverage of analytical techniques, pharmacokinetics, therapeutic indices, artificial intelligence and recent advances in toxicological studies.The book fills a gap in published literature and provides reliable information on; Analytical techniques in TDM and clinical toxicology TDM and pharmacokinetic studies TDM of drugs with narrow therapeutic indices Artificial intelligence in TDM and clinical toxicology Future directions and challenges

Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a book series that brings updated reviews to readers interested in advances in the development of pharmaceutical agents for the treatment of central nervous system (CNS) and other nerve disorders. The scope of the book series covers a range of topics including the medicinal chemistry, pharmacology, molecular biology and biochemistry of contemporary molecular targets involved in neurological and CNS disorders. Reviews presented in the series are mainly focused on clinical and therapeutic aspects of novel drugs intended for these targets. Frontiers in Clinical Drug Research - CNS and Neurological Disorders is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field of neurology.Volume 10 of the series continues to present novel information about new and interesting approaches to treat common neurological disorders, with a focus on neurodegeneration and pain medicine. The volume presents 7 detailed reviews in total.- Neurodegenerative disease: prevention and treatment through plant extracts therapy- Emerging novel approaches and recent advances in Parkinson`s disease treatment and diagnosis- Neurotrophic factors to combat neurodegeneration- Neural bases of executive function in ADHD children as assessed using FNIRS- Modulation of mesenchymal stem cells, glial cells and the immune system by oligodeoxynucleotides as a novel multi-target therapeutic approach against chronic pain- Chronic pain: focus on anticonvulsants- A review of the impact of testosterone on brain and aging-related decline in brain behavioural function

Comprehensive Pharmacology, Seven Volume Set is organized into twelve sections that explore therapeutic areas, with a total of 320 comprehensive articles and 6,800 pages of important findings. Sections contain highly detailed coverage of information that has been overseen by an editorial board made up of well-respected, field leading experts. The content in this book offers readers an in-depth and easily accessible reference work on every aspect of pharmacological research surrounding the pharmacology of all therapeutic applications of drugs, their mechanism of action and their therapeutic values. These elements are essential as drugs are almost never tested and developed in the actual therapeutic system, but rather in test systems from which parameters must be determined to predict activity in systems of varying ambient physiology. As different technologies rapidly evolve, there is an ever-increasing level of knowledge about the pharmacology of known drugs, along with increasing capability to utilize pharmacological systems to predict new drug activity, all of which must be communicated to professionals in varying fields. - Contains chapters that follow a consistent and templated approach, resulting in well-structured content that enhances user experience and appeal - Offers a comprehensive review on a wealth of information on pharmacology and how it utilizes concepts and techniques from a broad array of sciences, ranging from chemistry to physiology to medicine - Includes a wider use of color and multimedia content, with interactive features, links, computational modeling and animations to illustrate the effects of toxic substances in various contexts

Biopharmaceutics and Pharmacokinetics Considerations examines the history of biopharmaceutics and pharmacokinetics. The book provides a biopharmaceutics and pharmacokinetics approach to addressing issues in formulation development and ethical considerations in handling animals. Written by experts in the field, this volume within the Advances in Pharmaceutical Product Development and Research series deepens understanding of biopharmaceutics and pharmacokinetics within drug discovery and drug development. Each chapter delves into a particular aspect of this fundamental field to cover the principles, methodologies and technologies employed by pharmaceutical scientists, researchers and pharmaceutical industries to study the chemical and physical properties of drugs and the biological effects they produce. - Examines the most recent developments in biopharmaceutics and pharmacokinetics for pharmaceutical sciences - Covers the principles, methodologies and technologies of biopharmaceutics and pharmacokinetics - Focuses on the pharmaceutical sciences, but also encompasses aspects of toxicology, neuroscience, environmental sciences and nanotechnology

Recent Advancement in ProdrugsDrugs used as medicines have many limitations like low chemical stability, aqueous solubility, or oral absorption/bioavailability, rapid presystemic metabolism, toxicity, inadequate site specificity, or poor patient acceptance/compliance (unwanted adverse effects, unacceptable taste or odor, irritation or pain). Prodrugs design is an approach to overcome these limitations.Key features Covers recent advancements in development of prodrugs Presents balanced synthesis and applications of prodrug chemistry Discusses broad spectrum of prodrug categories and outlines industrial applications Reviews prodrugs in cancer nanomedicine, its therapy and treatment Elucidates mathematical models to study the kinetics of prodrugs This book covers recent advances in the design of prodrugs. It contains all the significant recent examples of prodrug chemistry developments and will aid academics and researchers seeking to generate new projects in the field.

Even though clozapine is the only drug with evidence-based efficacy in schizophrenia symptoms not responding to other agents, it is still under-prescribed in most countries around the world. The barriers for initiating clozapine are evident in both clinicians and patients. Prescribers mainly report delaying clozapine because of fear of severe side effects and lack of knowledge regarding management of side effects driven by stigmatic rather evidence-based views. Patients report reservations toward the need for safety regulation and blood tests. Enduring psychotic illness is often associated with high level of burden of symptoms, which does not allow progress into recovery process in the community. It is often the case that treatment with clozapine has a dramatic effect on symptoms, otherwise refractory. However, there cases in which there is only minor or no effect of the drug. In these cases, sometimes referred to as ultra-resistant schizophrenia, it is advised to optimise clozapine treatment using pharmacokinetic considerations and confirm sufficient clozapine serum levels using therapeutic drug monitoring. Further steps include precise diagnosis and management of other physical or psychiatric comorbidities, offering targeted psychotherapy such as CBT and family interventions and eventually to wait, as sometimes there are cases of late response. In this book we aimed at providing clinicians with practical, up-do-date knowledge to support their decision-making and safety management when prescribing clozapine. It is our hope that using the information in this book would encourage both prescribers and patients to consider clozapine treatment when it is needed, in a timely fashion. We believe that accurate and systematic information is a key for reducing anxiety and relieving stigma associated with clozapine treatment.

This is the second edition of a well-received book in the series “Drug Discovery and Evaluation” The completely revised new edition of the volume reflects the current state of the art in Clinical Pharmacology. Drug Discovery and Evaluation has become a more and more difficult, expensive and time-consuming process. The effect of a new compound has to be detected by in vitro and in vivo methods of pharmacology. The activity spectrum and the potency compared to existing drugs have to be determined. As these processes can be divided up stepwise we have designed a book series'Drug Discovery and Evaluation'in the form of a recommendation document. Clinical pharmacokinetics are performed in parallel with human studies on tolerability and therapeutic effects. Special studies according to various populations and different therapeutic indications are necessary. These items are covered in the third volume: „Methods in Clinical Pharmacology'. For the 2nd edition of this volume, the chapters have been revised and completely updated. A large number of assays were added. New chapters were included, such as pain, addiction, gene therapy, orphan diseases.

Nanotechnology Based Approaches for Tuberculosis Treatment discusses multiple nanotechnology-based approaches that may help overcome persisting limitations of conventional and traditional treatments. The book summarizes the types of nano drugs, their synthesis, formulation, characterization and applications, along with the most important administration routes. It also explores recent advances and achievements regarding therapeutic efficacy and provides possible future applications in this field. It will be a useful resource for investigators, pharmaceutical researchers, innovators and scientists working on technology advancements in the areas of targeted therapies, nano scale imaging systems, and diagnostic modalities in tuberculosis. - Addresses the gap between nanomedicine late discovery and early development of tuberculosis therapeutics - Explores tuberculosis nanomedicine standardization and characterization with newly developed treatment, diagnostic and treatment monitoring modalities - Covers the field thoroughly, from the pathogenesis of tuberculosis and multi-drug resistant mycobacterium tuberculosis, to treatment approaches using nanotechnology and different nanocarriers

This book provides an introduction to the principles of pharmacogenomics and precision medicine, followed by the pharmacogenomics aspects of major therapeutic areas such as cardiovascular disease, cancer, organ transplantation, psychiatry, infection, antithrombotic drugs. It also includes genotyping technology and therapeutic drug monitoring in Pharmacogenomics; ethical, Legal and Regulatory Issues; cost-effectiveness of pharmacogenetics-guided treatment; application of pharmacogenomics in drug discovery and development and clinical Implementation of Pharmacogenomics for Personalized Precision Medicine. The contributors of Pharmacogenomics in Precision Medicine come from a team of experts, including professors from academic institutions and practitioner from hospital. It will give an in-depth overview of the current state of pharmacogenomics in drug therapy for all health care professionals and graduate students in the era of precision medicine.

This book continues to be the definitive reference on drug metabolism with an emphasis on new scientific and regulatory developments. It has been updated based on developments that have occurred in the last 5 years, with new chapters on large molecules disposition, stereo-selectivity in drug metabolism, drug transporters and metabolic activation of drugs. Some chapters have been prepared by new authors who have emerged as subject area experts in the decade that has passed since publication of the first edition.

Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation, Second Edition, provides comprehensive coverage of the challenges and opportunities facing the therapeutic implications of pharmacogenomics from academic, regulatory, pharmaceutical, socio-ethical and economic perspectives. While emphasis is on the limitations in moving the science into drug development and direct therapeutic applications, this book also focuses on clinical areas with successful applications and important initiatives that have the ability to further advance the discipline. New chapters cover important topics such as pharmacogenomic data technologies, clinical testing strategies, cost-effectiveness, and pharmacogenomic education and practice guidelines. The importance of ethnicity is also discussed, which highlights phar,acogenomic diversity across Latin American populations.With chapters written by interdisciplinary experts and insights into the future direction of the field, this book is an indispensable resource for academic and industry scientists, graduate students and clinicians engaged in pharmacogenomics research and therapeutic implementation. - Provides viewpoints that focus on the scientific and translational challenges and opportunities associated with advancing the field of pharmacogenomics - Highlights progress in both the research and clinical areas of pharmacogenomics, as well as relevant implementation experience, challenges, and perspectives on direct-to-consumer genetic testing - Includes, where applicable, discussion points, review questions, and cases for self-assessment purposes and to facilitate in-depth discussion

Die Pharmakogenetik untersucht den Einfluss individueller genetischer Merkmale auf Wirkung und unerwünschte Wirkung von Arzneimitteln. Dieses Buch macht auf die Perspektiven der Pharmakogenetik für eine verbesserte Pharmakotherapie aufmerksam und stellt die praxisrelevanten, wichtigen Entwicklungen und Erkenntnisse der Forschung dar. Den Ärzten sollen Möglichkeiten aufgezeigt werden, anhand der Untersuchung genetischer Dispositionen von Patienten die Arzneimittelwirksamkeit zu optimieren und unerwünschte Arzneimittelwirkungen und Interaktionen zu minimieren.

Aging is a natural phenomenon that is peculiar to all living things. However, accumulating findings indicate that senescence could be postponed or prevented by certain approaches. Substantial evidence has emerged supporting the possibility of radical human health and lifespan extension, in particular through pharmacological modulation of aging. A number of natural dietary ingredients and synthetic drugs have been assumed to have geroprotective potential. In the development of anti-aging therapeutics, several cell, insect, and animal models may provide useful starting points prior to human studies.This book provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the fascinating historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.A timely and carefully edited collection of chapters by leading researchers in the field, this book will be a fascinating and useful resource for pharmacologists, gerontologists and any scientifically interested person wishing to know more about the current status of research into anti-aging remedies, challenges and opportunities.

The delivery of optimal pharmaceutical services to patients is a pivotal concern in the healthcare field. By examining current trends and techniques in the industry, processes can be maintained and improved. Pharmaceutical Sciences: Breakthroughs in Research and Practice provides comprehensive coverage of the latest innovations and advancements for pharmaceutical applications. Focusing on emerging drug development techniques and drug delivery for improved health outcomes, this book is ideally designed for medical professionals, pharmacists, researchers, academics, and upper-level students within the growing pharmaceutical industry.

Depression is a common worldwide mental illness, and one of the leading causes of disability. It is not exclusive for an age, social or income level. Antidepressants are used as a pharmacological treatment for depression. Currently available antidepressants have several limitations including a long time lag for treatment response, modest rates of efficacy and the side effects associated with its use. This book examines the different perspectives, medical uses and health implications that antidepressants have on patients.

Comprehensive Toxicology, Third Edition, Fifteen Volume Set discusses chemical effects on biological systems, with a focus on understanding the mechanisms by which chemicals induce adverse health effects. Organized by organ system, this comprehensive reference work addresses the toxicological effects of chemicals on the immune system, the hematopoietic system, cardiovascular system, respiratory system, hepatic toxicology, renal toxicology, gastrointestinal toxicology, reproductive and endocrine toxicology, neuro and behavioral toxicology, developmental toxicology and carcinogenesis, also including critical sections that cover the general principles of toxicology, cellular and molecular toxicology, biotransformation and toxicology testing and evaluation. Each section is examined in state-of-the-art chapters written by domain experts, providing key information to support the investigations of researchers across the medical, veterinary, food, environment and chemical research industries, and national and international regulatory agencies. Thoroughly revised and expanded to 15 volumes that include the latest advances in research, and uniquely organized by organ system for ease of reference and diagnosis, this new edition is an essential reference for researchers of toxicology. - Organized to cover both the fundamental principles of toxicology and unique aspects of major organ systems - Thoroughly revised to include the latest advances in the toxicological effects of chemicals on the immune system - Features additional coverage throughout and a new volume on toxicology of the hematopoietic system - Presents in-depth, comprehensive coverage from an international author base of domain experts

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 39 presents the latest on a variety of topics, with new chapters in this volume covering Central nervous system stimulants and drugs that suppress appetite, Antidepressant drugs, Lithium, Drugs of abuse, Hypnotics and sedatives, Antipsychotic Drugs, Antiepileptic Drugs, Opioid analgesics and narcotic antagonists, Anti-inflammatory and antipyretic analgesics and drugs used in gout, General anesthetics and therapeutic gases, Local anesthetics, Neuromuscular blocking agents and skeletal muscle relaxants, and more. First published in 1977, and continually published as a yearly update, this series provides clinicians and medical investigators with a reliable and critical survey of new data and trends in the area of adverse drug reactions and interactions, with an international team of specialists contributing their expertise each year. - Provides a critical yearly survey of the new data and trends regarding the side effects of drugs - Authored and reviewed by worldwide pioneers in the clinical and practice sciences - Presents an essential clinical on the side effects of drugs for practitioners and healthcare professionals alike

The second edition of Neuroimmune Pharmacology bridges the disciplines of neuroscience, immunology and pharmacology from the molecular to clinical levels with particular thought made to engage new research directives and clinical modalities.Bringing together the foremost field authorities from around the world, Neuroimmune Pharmacology will serve as an invaluable resource for the basic and applied scientists of the current decade and beyond.

In light of the rising cost of healthcare and the overall challenges associated with delivering quality care to patients across regions, scientists and pharmacists are exploring new initiatives in drug discovery and design. One such initiative is the adoption of information technology and software applications to improve healthcare and pharmaceutical processes. Software Innovations in Clinical Drug Development and Safety is a comprehensive resource analyzing the integration of software engineering for the purpose of drug discovery, clinical trials, genomics, and drug safety testing. Taking a multi-faceted approach to the application of computational methods to pharmaceutical science, this publication is ideal for healthcare professionals, pharmacists, computer scientists, researchers, and students seeking the latest information on the architecture and design of software in clinical settings, the impact of clinical technologies on business models, and the safety and privacy of patients and patient data. This timely resource features a well-rounded discussion on topics pertaining to the integration of computational methods in pharmaceutical science and practice including, the impact of software integration on business models, patient safety concerns, software architecture and design, and data security.

The first authoritative textbook specifically addressing issues of the field, this book delivers a focused discussion on several themes in psychiatry while providing a sound background on pharmacovigilance. Internationally-recognised researchers, clinicians and pharmacovigilance experts contributed to this textbook, giving it the benefit of different perspectives and years of experience. Pharmacovigilance in psychiatry provides a thorough introduction to this field but goes on to explore advanced themes such as methodologies and resources used for pharmacovigilance in psychiatry, challenges as well as most recent developments to this field, making it suitable for under-graduates, graduate and post-doctoral students and persons working pharmacovigilance who seek to broaden their knowledge on this subject.

This book provides basic and applied knowledge about monoamine oxidase inhibitors (MAOIs), their classification, and clinical application as neuroprotective agents and will be a valuable source of new knowledge for doctors, patients, medical students, teachers, researchers, and basic biomedical scientists interested in learning the appropriate clinical application of MAOIs without any misunderstanding for the prevention and/or treatment of neurological and neuropsychiatric disorders. The book will be of immediate interest to patients suffering from Parkinson's disease (PD), Alzheimer's disease (AD), post-traumatic stress disorders (PTSD), panic disorders, attention deficit hyperactivity disorders (ADHD), and major depression. Physicians interested in learning more about MAOIs and their molecular and pharmacological mechanism of action will highly benefit from the book's clinically-interesting contents. In general, this book will be a valuable source of knowledge for the basic researcher, clinically useful for the physician, and therapeutically-beneficial for the patients. The book can also serve as a guide for Masters and Ph.D students interested in conducting research on MAOIs. Particularly, MD doctors, students, and professors will find this book interesting to enhance their basic knowledge about MAOIs and their potential benefits and adverse effects for the better clinical management of drug-resistant PD, AD, and MDDs. Furthermore, recent knowledge regarding the molecular mechanism of MAOIs-mediated protection at the cellular, molecular, and genetic level is thought-provoking and motivates the young scientists to augment research on developing novel drugs with minimum or no adverse effects. It is envisaged that future research on specific CB-targeted MAOIs will have superior pharmacogenomics profiles, enhanced margin of safety, maximum therapeutic index, and minimum or no adverse effects.

Here's the in-depth information you need to be a safe and effective prescriber of medications. This exceptional text builds your knowledge of pharmacology by first providing an overview of pharmacologic principles and then teaching you how to apply those principles to clinical practice. Focusing on applying pharmacologic scientific knowledge to clinical practice, it explains diagnostic and treatment reasoning and rational drug selection, while providing useful clinical pearls from experienced practitioners. The use of a Rational Drug Selection process enables you to understand how to prescribe the right drug...for the right patient...at the right time! Updated to reflect the most recent scientific knowledge and clinical practice in the field, the 4th Edition provides everything you need to confidently tackle the ever-changing and increasing volume of pharmacology information.

This issue of the Clinics in Laboratory Medicine on “Pharmacogenomics” is being edited by Drs. Roland Valdes and Kristen Reynolds and will cover a wide variety of topics, including but not limited to, fundamentals of pharmacology, a review of pharmacogenetics guidelines, pharmacogenetic testing in pain management, pharmacogenetics of pain management, clinical and economic impact of pharmacogenetic genotyping analysis, exosome analysis in lab medicine, and implementation of pharmacogenetics in developing countries.

Cytochromes are proteins that catalyze electron transfer reactions of well-known metabolic pathways and are classified in various superfamilies. The CYP, or P450, superfamily accounts for 90% of the oxidative metabolism of clinical drugs. One member of this superfamily, P450 2D6 (or CYP2D6), singlehandedly metabolizes about 25% of all medications in the human liver. Cytochrome P450 2D6: Structure, Function, Regulation, and Polymorphism reviews the current knowledge of CYP2D6 as well as the maturing body of evidence indicating its significance to clinical and pharmacological researchers and practitioners.This book focuses on the critical role CYP2D6 plays in the human liver. It examines the genetic, epigenetic, physiological, pathological, and structural factors of the gene that govern the highly variable metabolism of a number of drugs in clinical use. It highlights the impact of the functional roles of CYP2D6 on clinical practice and drug development and also discusses implications for precise medicine, strategies to avoid adverse drug reactions, and paths for future research.Cytochrome P450 2D6 is a unique, valuable book focusing on a single but immensely powerful human gene. It provides the first single source of comprehensive information on CYP2D6 that serves as an important reference for medical, biomedical, pharmaceutical, and nursing researchers, practitioners, and students.

Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions, Sixteenth Edition, Seven Volume Set builds on the success of the 15 previous editions, providing an extensively reorganized and expanded resource that now comprises more than 1,500 individual drug articles with the most complete coverage of adverse reactions and interactions found anywhere. Each article contains detailed and authoritative information about the adverse effects of each drug, with comprehensive references to the primary literature, making this a must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company. The online version of the book provides an unparalleled depth of coverage and functionality by offering convenient desktop access and enhanced features such as increased searchability, extensive internal cross-linking, and fully downloadable and printable full-text, HTML or PDF articles. - Enhanced encyclopedic format with drug monographs now organized alphabetically - Completely expanded coverage of each drug, with more than 1,500 drug articles and information on adverse reactions and interactions - Clearer, systematic organization of information for easier reading, including case histories to provide perspective on each listing - Extensive bibliography with over 40,000 references - A must–have reference work for any academic or medical library, pharmacologist, regulatory organization, hospital dispensary, or pharmaceutical company

This book is a comprehensive resource on psychotropic medications, detailing the latest methods for defining their characteristics, their use in different patient populations, and drug-drug interactions; an important collection of information forclinicians, students, researchers, and members of the pharmaceutical industry alike. The first section provides the foundational principles of these drugs. Mathematical modeling of parameters that affect their entryto,and exit from, the central nervous system (CNS) compartment are presented on an individual basis and then applied to target populations with specific disease states. Methods and characteristics that inform the transfer of these drugs from the laboratory bench to use in patient care are discussed, including imaging techniques, genetics and physiological barriers, such as the blood-brain barrier. The second section describes the characteristics of specific agents,nominally arranged intodifferent therapeutic categories andwith reference crossover use in different disease states. The pharmacologic characteristics of different drug formulations are explored in the context of their ability to improve patient adherence. The third section focuses on drug-drug interactions.Psychotropic medications from different categories are frequently prescribed together,or alongside medications used to treat comorbid conditions, and the information provided is directly relevant to the clinic, as a result. The clinical application of pharmacokinetics and pharmacodynamics of CNS agents has made significant progress over the past 50 years and new information is reported by numerous publications in psychiatry, neurology, and pharmacology.Our understanding of the interrelationship between these medications, receptors, drug transporters, as well as techniques for measurement and monitoring their interactions,isfrequently updated. However, with information presented on a host of different platforms, and in differentformats, obtaining the full picture can be difficult. This title aims to collate this information into a single source that can be easily interpreted and applied towards patient care by the clinical practitioner, and act as a reference for all others who have an interest in psychopharmacological agents.

Pharmacogenomics supports personalized medicine by translating genome-based knowledge into clinical practice, offering enhanced benefit for patients and health-care systems at large. Current routine practice for diagnosing and treating patients is conducted by correlating parameters such as age, gender and weight with risks and expected treatment outcomes. In the new era of personalized medicine the healthcare provider is equipped with improved ability to prevent, diagnose, treat and predict outcomes on the basis of complex information sources, including genetic and genomic data. Targeted therapy and reliable prediction of expected outcomes offer patients access to better healthcare management, by way of identifying the therapies effective for the relevant patient group, avoiding prescription of unnecessary treatment and reducing the likelihood of developing adverse drug reactions.

Principles of Translational Science in Medicine: From Bench to Bedside, Second Edition, provides an update on major achievements in the translation of research into medically relevant results and therapeutics. The book presents a thorough discussion of biomarkers, early human trials, and networking models, and includes institutional and industrial support systems. It also covers algorithms that have influenced all major areas of biomedical research in recent years, resulting in an increasing numbers of new chemical/biological entities (NCEs or NBEs) as shown in FDA statistics. The book is ideal for use as a guide for biomedical scientists to establish a systematic approach to translational medicine. - Provides an in-depth description of novel tools for the assessment of translatability of trials to balance risk and improve projects at any given stage of product development - New chapters deal with translational issues in the fastest growing population (the elderly), case studies, translatability assessment tools, and advances in nanotherapies - Details IPR issues of translation, especially for public-private-partnerships - Contains contributions from world leaders in translational medicine, including the former NIH director and authorities from various European regulatory institutions

This authoritative Fourth Edition summarizes the advances of the past decade concerning the structure, mechanism, and biochemistry of cytochrome P450 enzymes, with sufficient coverage of earlier work to make each chapter a comprehensive review of the field. Thirteen chapters are divided into two detailed volumes, the first covering the fundamentals of cytochrome P450 biochemistry, as well as the microbial, plant, and insect systems, and the second exclusively focusing on mammalian systems.Volume 1 begins with an exploration of the biophysics and mechanistic enzymology of cytochrome P450 enzymes, with a discussion of the structures of P450 enzymes and their electron donor partners, the mechanisms of oxygen activation and substrate oxidation, and the approaches and nature of cytochrome P450 inhibition. Two more chapters discuss the nature and roles of cytochrome P450 enzymes in microbes, plants and insects, and an eighth chapter is a survey of the potential utility of P450 enzymes in biotechnology. The first chapter of Volume 2 examines the roles of P450 enzymes in mammals, mainly humans. Four further chapters then deal with the genetic and hormonal regulation of P450 enzymes and their specific roles in the processing of sterols and lipids. Cytochrome P450: Structure, Mechanism, and Biochemistry is a key resource for scientists, professors, and students interested in fields as diverse as biochemistry, chemistry, biophysics, molecular biology, pharmacology and toxicology.

This book covers all the pharmacology you need, from basic science pharmacology and pathophysiology, through to clinical pharmacology to therapeutics, in line with the integrated approach of new medical curricula. The first section covers the basic principles, and the rest is organised by body systems. The book ends with sections on toxicity and prescribing practice.Integrates basic science pharmacology, clinical pharmacology and therapeutics Brief review of pathophysiology of major diseases Case histories and multiple choice questions (and answers) Tabular presentation of all common drugs within each class Section on further reading Kinetics chapter simplified with more practical examplesIncludes more on genetic issuesDrug tables made more concise to make information more accessibleFully updated to reflect current clinical practice

This book encompasses major progress and future directions in cytochrome P450 (P450) research. Included are contributions by pioneers in the discovery of P450, with chapters on the molecular and functional properties of P450 and cutting-edge applications knowledge from various fields. P450 research has its roots in metabolism, but the true beginning was in 1962 with the publication by Tsuneo Omura and Ryo Sato in The Journal of Biological Chemistry on their discovery of the cytochrome. Following this groundbreaking study, over the last half-century, research has revealed that many forms of P450 exist in animals, plants and microorganisms. P450 research has expanded into many different fields including medicine, agriculture and biotechnology and has drawn the attention of industries for its bioengineering applications, such as drug development and creation of the “blue rose”. Also, research on nuclear receptors, which has grown out of research on the regulatory mechanisms of P450 genes, has become an important area in biology, medical science, pharmacology and clinical medicine—for example, with recent developments in personalized medicines. This book will draw readers into the important and exciting world of P450 and will encourage young students and scientists in P450 research to continue expanding the field via new approaches.

It is often implied that antipsychotic-induced extrapyramidal side-effects are irrelevant to modern psychiatric therapeutics, rendered historic by newer, better treatments. This myth arises from limited awareness of the depth and breadth of neurological disruption antipsychotics can mediate. This volume discusses the extensive clinical boundaries of acute dystonias, drug-induced parkinsonism, akathisia and tardive dyskinesia, providing demographic and epidemiological context while illustrating how prescribing choices impact powerfully on their development. This new edition has been thoroughly updated and rewritten to include recent data, expanded references and a new chapter on the concept of'atypical'antipsychotics. Written in a light, engaging style, liberally illustrated with clinical examples, it also invites readers to consider ongoing controversies - subjective drug effects, the relationship between'akathisia'and restless legs, the status of the concept of'atypicality', and so on. Informative reading for trainees as well as established practitioners in the fields of psychiatry, neurology, primary care and geriatrics.

Global Clinical Trials for Alzheimer's Disease is a handy one-stop reference for researchers and physicians planning and conducting global clinical trials in this area. This book addresses important considerations that may arise during the successful design and execution of these trials, including site selection, local regulatory issues, pharmacogenomics, ethical matters and much more. Given the saturation of traditional clinical trial markets and the worldwide progression of Alzheimer's disease, there is a need to focus on clinical trials in emerging markets and developing countries. This book provides you with a practical approach to recognizing the opportunities and tackling the challenges that are present during the planning and execution of global clinical trials for Alzheimer's disease. - Written by leading experts with hands-on experience in designing and running global Alzheimer's disease and other neurodegenerative diseases clinical trials - A step-by-step guide that provides critical information on the design, conduct and standardization necessary to effectively execute clinical trials and accelerate drug development in this area - Includes practical examples, ethical considerations, lessons learned and other valuable tools to aid the planning and implementation of Alzheimer's disease global clinical trials in emerging markets and developing countries

Sets the foundation for safer, more effective drug therapies With this book as their guide, readers will discover how to apply our current understanding of the pharmacogenomics of drug transporters to advance their own drug discovery and development efforts. In particular, the book explains how new findings in the field now enable researchers to more accurately predict drug interactions and adverse drug reactions. Moreover, it sets the foundation for the development of drug therapies that are tailored to an individual patient's genetics. Pharmacogenomics of Human Drug Transporters serves as a comprehensive guide to how transporters regulate the absorption, distribution, and elimination of drugs in the body as well as how an individual's genome affects those processes. The book's eighteen chapters have been authored by a team of leading pioneers in the field. Based on their own laboratory and clinical experience as well as a thorough review of the literature, these authors explore all facets of drug transporter pharmacogenomics, including: Individual drug transporters and transporter families and their clinical significance Principles of altered drug transport in drug–drug interactions, pharmacotherapy, and personalized medicine Emerging new technologies for rapid detection of genetic polymorphisms Clinical aspects of genetic polymorphisms in major drug transporter genes Future research directions of drug transporter pharmacogenomics and the prospect of individualized medicine Pharmacogenomics of Human Drug Transporters opens the door to new drug discovery and development breakthroughs leading to safer and more effective customized drug therapies.The book is recommended for pharmaceutical scientists, biochemists, pharmacologists, clinicians, and genetics and genomics researchers.

Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and -- together with the previous volumes -- constitutes the first systematic approach to drug analogue development.

Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation includes discussions and viewpoints from the academic, regulatory, pharmaceutical, clinical, socio-ethical and economic perspectives. Each chapter presents an overview of the potential or opportunity within the areas discussed and also outlines foreseeable challenges and limitations in moving pharmacogenomics into drug development and direct therapeutic applications. This edited book contains review questions for a more in-depth analysis of the implications of pharmacogenomics and discussion points to generate ideas on best to move the field forward. Clinical pearls and case studies are used to illustrate real-life experiences and both successful and unsuccessful applications. Tables, figures, and annotations are included throughout the book to facilitate understanding and further reference. - Multi-contributed book and chapters are written by contributors who are experts in their field - Provides perspectives from those involved in all aspects of pharmacogenomics—including academic, regulatory, economic, industry and medical—to illustrate how all of the pieces fit together and where the challenges may be - Includes case studies of both successful and unsuccessful applications so readers can consider the potential and challenges in moving the science into drug development and direct therapeutic applications - Chapters contain discussion questions and clinical pearls and enable readers to reflect on how to move pharmacogenomics forward and apply these observations and useful tips to their own work and research

Band III der bekannten Reihe Neuropsychopharmaka stellt in der Neuauflage die aktuellsten medizinischen Präparate und klinischen sowie grundlagenorientierten Ergebnisse zum Thema Depressionssyndrom bzw. Antidepressiva vor. Der Band wurde in Anlehnung an die bereits erfolgten Neuauflagen der Bände IV und V neu gegliedert. Grundlegende Kapitel wurden vorangestellt, die eine Begründung für die im Buch dargestellten Therapiestrategien geben. Der Text wird durch Tabellen, Figuren und einen Medikamentenanhang anschaulich ergänzt. Die Neubearbeitung erfolgte durch eine große Anzahl von renommierten Psychiatern, Pharmakologen und Neurochemikern aus dem gesamten deutschsprachigen Raum, die für eine ausgewogene Darstellung sorgen. Das Buch liefert als einzigartiges Handbuch und Nachschlagewerk rasche Information zu allen Medikamenten. Die leserfreundliche Gliederung (detailliertes Inhaltsverzeichnis, ausführliches Stichwortverzeichnis, Tabellenwerk im Anhang) bietet die Möglichkeit, rasch eine Antwort zu erhalten.

Most medicines have never been adequately tested for safety and efficacy in pediatric populations and preterm, infants and children are particularly vulnerable to adverse drug reactions.Pediatric Drug Development: Concepts and Applications, Second Edition, addresses the unique challenges in conducting effective drug research and development in pediatric populations.This new edition covers the legal and ethical issues of consent and assent, the additional legal and safety protections for children, and the appropriate methods of surveillance and assessment for children of varying ages and maturity, particularly for patient reported outcomes. It includes new developments in biomarkers and surrogate endpoints, developmental pharmacology and other novel aspects of global pediatric drug development. It also encompasses the new regulatory initiatives across EU, US and ROW designed to encourage improved access to safe and effective medicines for children globally.From an international team of expert contributors Pediatric Drug Development: Concepts and Applications is the practical guide to all aspects of the research and development of safe and effective medicines for children.

The book Modern Medical Toxicology discusses on medical aspects of toxicology and the toxicity of some important drugs along with their pharmacotherapeutic uses, toxicokinetics, diagnosis, management and forensic issues. It also covers the practical guidelines in the treatment of poisoning. The book is divided into twelve sections which include general principles, corrosive (caustic) poisons, chemical poisons, organic poisons, neurotoxic poisons, cardiovascular poisons, asphyxiant poisons, hydrocarbons and pesticides, miscellaneous drugs and poisons, food poisons, substance abuse, and analytical toxicology. The goal of modern medical toxicology (MMT) is to provide useful clinical information on poisons and poisoning to emergency room (ER) physicians, medical students, interns, residents, nurses, pharmacists, and other health care professionals in a concise, complete, and accurate manner. This book mainly concentrates on important fundamental information on commonly encountered poisons and how they are misused.